» Articles » PMID: 35289316

Genetically Programmed Alternative Splicing of NEMO Mediates an Autoinflammatory Disease Phenotype

Abstract

Host defense and inflammation are regulated by the NF-κB essential modulator (NEMO), a scaffolding protein with a broad immune cell and tissue expression profile. Hypomorphic mutations in inhibitor of NF-κB kinase regulatory subunit gamma (IKBKG) encoding NEMO typically present with immunodeficiency. Here, we characterized a pediatric autoinflammatory syndrome in 3 unrelated male patients with distinct X-linked IKBKG germline mutations that led to overexpression of a NEMO protein isoform lacking the domain encoded by exon 5 (NEMO-Δex5). This isoform failed to associate with TANK binding kinase 1 (TBK1), and dermal fibroblasts from affected patients activated NF-κB in response to TNF but not TLR3 or RIG-I-like receptor (RLR) stimulation when isoform levels were high. By contrast, T cells, monocytes, and macrophages that expressed NEMO-Δex5 exhibited increased NF-κB activation and IFN production, and blood cells from these patients expressed a strong IFN and NF-κB transcriptional signature. Immune cells and TNF-stimulated dermal fibroblasts upregulated the inducible IKK protein (IKKi) that was stabilized by NEMO-Δex5, promoting type I IFN induction and antiviral responses. These data revealed how IKBKG mutations that lead to alternative splicing of skipping exon 5 cause a clinical phenotype we have named NEMO deleted exon 5 autoinflammatory syndrome (NDAS), distinct from the immune deficiency syndrome resulting from loss-of-function IKBKG mutations.

Citing Articles

Single-Cell RNA Sequencing in Incontinentia Pigmenti With Neonatal Encephalopathy Reveals Broad Immune Activation Moderated by Steroids.

Mohammad S, Han V, Gloss B, Keating B, Nishida H, Lau X Neurol Neuroimmunol Neuroinflamm. 2025; 12(3):e200358.

PMID: 40020213 PMC: 11876987. DOI: 10.1212/NXI.0000000000200358.


Non-Skewed X-inactivation Results in NF-κB Essential Modulator (NEMO) Δ-exon 5-autoinflammatory Syndrome (NEMO-NDAS) in a Female with Incontinentia Pigmenti.

Eigemann J, Janda A, Schuetz C, Lee-Kirsch M, Schulz A, Hoenig M J Clin Immunol. 2024; 45(1):1.

PMID: 39264518 PMC: 11393190. DOI: 10.1007/s10875-024-01799-2.


Get Spliced: Uniting Alternative Splicing and Arthritis.

van Haaren M, Steller L, Vastert S, Calis J, van Loosdregt J Int J Mol Sci. 2024; 25(15).

PMID: 39125692 PMC: 11311815. DOI: 10.3390/ijms25158123.


Infection risk in patients with autoimmune cytopenias and immune dysregulation treated with mycophenolate mofetil and sirolimus.

Comella M, Palmisani E, Mariani M, DellOrso G, Licciardello M, Giarratana M Front Immunol. 2024; 15:1415389.

PMID: 38873600 PMC: 11169563. DOI: 10.3389/fimmu.2024.1415389.


Altered X-chromosome inactivation predisposes to autoimmunity.

Huret C, Ferraye L, David A, Mohamed M, Valentin N, Charlotte F Sci Adv. 2024; 10(18):eadn6537.

PMID: 38701219 PMC: 11068014. DOI: 10.1126/sciadv.adn6537.


References
1.
Pomerantz J, Baltimore D . NF-kappaB activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase. EMBO J. 1999; 18(23):6694-704. PMC: 1171732. DOI: 10.1093/emboj/18.23.6694. View

2.
Soderberg O, Gullberg M, Jarvius M, Ridderstrale K, Leuchowius K, Jarvius J . Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods. 2006; 3(12):995-1000. DOI: 10.1038/nmeth947. View

3.
Orstavik K, Kristiansen M, Knudsen G, Storhaug K, Vege A, Eiklid K . Novel splicing mutation in the NEMO (IKK-gamma) gene with severe immunodeficiency and heterogeneity of X-chromosome inactivation. Am J Med Genet A. 2005; 140(1):31-9. DOI: 10.1002/ajmg.a.31026. View

4.
Bruni D, Sebastia J, Dunne S, Schroder M, Butler M . A novel IRAK1-IKKε signaling axis limits the activation of TAK1-IKKβ downstream of TLR3. J Immunol. 2013; 190(6):2844-56. DOI: 10.4049/jimmunol.1202042. View

5.
Audry M, Ciancanelli M, Yang K, Cobat A, Chang H, Sancho-Shimizu V . NEMO is a key component of NF-κB- and IRF-3-dependent TLR3-mediated immunity to herpes simplex virus. J Allergy Clin Immunol. 2011; 128(3):610-7.e1-4. PMC: 3164951. DOI: 10.1016/j.jaci.2011.04.059. View